Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen as Adjuvant to HER2 Vaccine in Breast Cancer
NCT01355393Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jul 2011
- Primary completion
- Nov 2013
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod in breast cancer, sponsored by University of Washington. Started Jul 2011; status: completed.
02
Drugs
rintatolimod
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01355393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01355393.